The independent medical news service

Previously treated patients with HER2-positive metastatic breast cancer derive a significant progression-free survival benefit from trastuzumab deruxtecan relative to trastuzumab emtansine, find the DESTINY-Breast03 investigators.

Adding carboplatin to neoadjuvant paclitaxel is sufficient to boost the outcomes of patients with triple-negative breast cancer, with no further improvement from the addition of veliparib to the dual regimen, confirms a follow-up analysis of the BrighTNess trial.

Residual cancer burden offers prognostic information after neoadjuvant chemotherapy across breast cancer subtypes and treatments, show data from I-SPY2.

Young women who undergo mastectomy for breast cancer report poorer quality of life than those treated with breast conserving therapy more than 5 years after surgery, particularly when they also receive radiotherapy, research shows.

The number of new cancer diagnoses during the first year of the COVID-19 pandemic was lower than in the prepandemic period, report US researchers.

Cardioprotective pharmacologic therapy may be effective against anthracycline-related subclinical heart damage in women with nonmetastatic breast cancer, with bisoprolol potentially offering greater benefits than ramipril, interim SAFE study data suggest.